Search Results

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, and Foundation Medicine, Inc. are pleased to announce a partnership aimed to impact the care of patients with late-stage colorectal cancer undergoing surgery.

Qu Biologics Inc. is pleased to announce, in partnership with TransBIOTech (Quebec), being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering.

Qu Biologics Inc. is pleased to announce that its Phase 2 clinical trial in late-stage colon cancer, PERIOP-06, was awarded CAD$400,000 in grant funding by the Accelerating Clinical Trial Canadian Consortium.

Qu Biologics Inc. is pleased to announce the appointment of Matt Cahill MBA JD PhD, as Chief Operating Officer.

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is excited to announce a new collaboration with Associate Professor Jonas Fuxe and his research team at the Karolinska Institute (KI) in Stockholm, Sweden, to characterize the molecular targets of Qu’s SSI therapy at the tissue level that lead to resolution of disease.

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today reported financial results and recent business highlights for its first quarter ended March 31, 2024.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, announced its first quarter 2024 financial results and provided a business update.

Samsung Biologics, a global contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2024.

Qu Biologics Inc. is pleased to announce the closing of a USD$12M equity financing to enable expansion of Qu’s team, initiation of an additional three Phase 2 clinical studies, and the acceleration of Qu’s novel immunomodulation platform.

Theriva™ Biologics reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.